Net Income (Loss) Attributable to Parent of VitaNova Life Sciences Corp from 25 Jan 2017 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
VitaNova Life Sciences Corp quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 25 Jan 2017 to 31 Oct 2025.
  • VitaNova Life Sciences Corp Net Income (Loss) Attributable to Parent for the quarter ending 31 Oct 2025 was $35,810, a 9.7% increase year-over-year.
  • VitaNova Life Sciences Corp Net Income (Loss) Attributable to Parent for the twelve months ending 31 Oct 2025 was $862,819, a 470% increase year-over-year.
  • VitaNova Life Sciences Corp annual Net Income (Loss) Attributable to Parent for 2024 was $850,746, a 504% increase from 2023.
  • VitaNova Life Sciences Corp annual Net Income (Loss) Attributable to Parent for 2023 was $140,865.
  • VitaNova Life Sciences Corp annual Net Income (Loss) Attributable to Parent for 2022 was $24,227, a 117% decline from 2021.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

VitaNova Life Sciences Corp Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $862,819 $35,810 +$3,163 +9.7% 01 Aug 2025 31 Oct 2025 10-Q 15 Dec 2025 2026 Q2
Q2 2025 $859,656 $46,301 +$8,910 +16% 01 May 2025 31 Jul 2025 10-Q 15 Dec 2025 2026 Q2
Q1 2025 $850,746 $800,332 +$632,413 +377% 01 Feb 2025 30 Apr 2025 10-K 24 Jul 2025 2025 FY
Q4 2024 $218,333 $72,978 +$67,030 +1127% 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025 2025 Q3
Q3 2024 $151,303 $32,647 +$41,402 01 Aug 2024 31 Oct 2024 10-Q 15 Dec 2025 2026 Q2
Q2 2024 $109,901 $55,211 -$30,964 -128% 01 May 2024 31 Jul 2024 10-Q 15 Dec 2025 2026 Q2
Q1 2024 $140,865 $167,919 +$172,304 01 Feb 2024 30 Apr 2024 10-K 24 Jul 2025 2025 FY
Q4 2023 $31,439 $5,948 +$30,525 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025 2025 Q3
Q3 2023 $61,964 $8,755 -$11,356 -437% 01 Aug 2023 31 Oct 2023 10-Q 17 Mar 2025 2025 Q3
Q2 2023 $50,608 $24,247 -$26,381 -1236% 01 May 2023 31 Jul 2023 10-Q 17 Mar 2025 2025 Q3
Q1 2023 $24,227 $4,385 +$22,422 +84% 01 Feb 2023 30 Apr 2023 10-K 29 Jul 2024 2024 FY
Q4 2022 $46,649 $24,577 -$33,494 -376% 01 Nov 2022 31 Jan 2023 10-Q 11 Mar 2024 2024 Q3
Q3 2022 $13,155 $2,601 -$12,408 -83% 01 Aug 2022 31 Oct 2022 10-Q 11 Mar 2024 2024 Q3
Q2 2022 $747 $2,134 -$140,429 -99% 01 May 2022 31 Jul 2022 10-Q 11 Mar 2024 2024 Q3
Q1 2022 $139,682 $26,807 -$1,244 -4.9% 01 Feb 2022 30 Apr 2022 10-K 15 May 2023 2023 FY
Q4 2021 $140,926 $8,917 +$11,816 01 Nov 2021 31 Jan 2022 10-Q 16 Feb 2023 2023 Q3
Q3 2021 $129,110 $15,009 +$27,394 01 Aug 2021 31 Oct 2021 10-Q 16 Feb 2023 2023 Q3
Q2 2021 $101,716 $142,563 +$153,810 01 May 2021 31 Jul 2021 10-Q 16 Feb 2023 2023 Q3
Q1 2021 $52,094 $25,563 +$774 +2.9% 01 Feb 2021 30 Apr 2021 10-K 16 May 2022 2022 FY
Q4 2020 $52,868 $2,899 +$3,695 +56% 01 Nov 2020 31 Jan 2021 10-Q 17 Feb 2022 2022 Q3
Q3 2020 $56,563 $12,385 +$7,134 +37% 01 Aug 2020 31 Oct 2020 10-Q 10 Nov 2021 2021 Q2
Q2 2020 $63,697 $11,247 +$8,637 +43% 01 May 2020 31 Jul 2020 10-Q 10 Nov 2021 2021 Q2
Q1 2020 $72,334 $26,337 -$12,741 -94% 01 Feb 2020 30 Apr 2020 10-K 01 Jul 2021 2021 FY
Q4 2019 $59,593 $6,594 +$30,102 +82% 01 Nov 2019 31 Jan 2020 10-Q 21 Jun 2021 2021 Q3
Q3 2019 $89,695 $19,519 +$20,530 +51% 01 Aug 2019 31 Oct 2019 10-Q 21 Jun 2021 2021 Q3
Q2 2019 $110,225 $19,884 -$4,058 -26% 01 May 2019 31 Jul 2019 10-Q 21 Jun 2021 2021 Q3
Q1 2019 $106,167 $13,596 -$9,402 -224% 01 Feb 2019 30 Apr 2019 10-K 05 Aug 2020 2020 FY
Q4 2018 $96,765 $36,696 -$23,946 -188% 01 Nov 2018 31 Jan 2019 10-Q 20 Mar 2020 2020 Q3
Q3 2018 $72,819 $40,049 -$45,829 -793% 01 Aug 2018 31 Oct 2018 10-Q 06 Dec 2019 2020 Q2
Q2 2018 $26,990 $15,826 -$25,395 -265% 01 May 2018 31 Jul 2018 10-Q 12 Sep 2019 2020 Q1
Q1 2018 $1,595 $4,194 +$2,981 +42% 01 Feb 2018 30 Apr 2018 10-K 30 Jul 2019 2019 FY
Q4 2017 $4,576 $12,750 01 Nov 2017 31 Jan 2018 10-Q 15 Mar 2019 2019 Q3
Q3 2017 $5,780 01 Aug 2017 31 Oct 2017 10-Q 18 Dec 2017 2018 Q2
Q2 2017 $9,569 01 May 2017 31 Jul 2017 10-Q 17 Aug 2018 2019 Q1
Q1 2017 $7,175 10 Jan 2017 30 Apr 2017 10-K 17 Jul 2018 2018 FY

VitaNova Life Sciences Corp Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $850,746 +$709,881 +504% 01 May 2024 30 Apr 2025 10-K 24 Jul 2025 2025 FY
2023 $140,865 +$165,092 01 May 2023 30 Apr 2024 10-K 24 Jul 2025 2025 FY
2022 $24,227 -$163,909 -117% 01 May 2022 30 Apr 2023 10-K 29 Jul 2024 2024 FY
2021 $139,682 +$191,776 01 May 2021 30 Apr 2022 10-K 15 May 2023 2023 FY
2020 $52,094 +$20,240 +28% 01 May 2020 30 Apr 2021 10-K 16 May 2022 2022 FY
2019 $72,334 +$33,833 +32% 01 May 2019 30 Apr 2020 10-K 01 Jul 2021 2021 FY
2018 $106,167 -$104,572 -6556% 01 May 2018 30 Apr 2019 10-K 05 Aug 2020 2020 FY
2017 $1,595 +$5,580 +78% 01 May 2017 30 Apr 2018 10-K 30 Jul 2019 2019 FY
2016 $7,175 26 Jan 2016 25 Jan 2017 10-K 17 Jul 2018 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.